Lucius LuciXaz Ixazomib 4mg

Product Information

• Product name: LuciXaz Ixazomib 4mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Ixazomib
• Current strength: 4mg
• SKU: LU-ITEM-129
• Site category: myeloma, other cancer

Product Summary

LuciXaz Ixazomib 4mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Ixazomib is the active ingredient used for this product page. Public prescribing information for Ixazomib was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines.

Reference Indications

Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Limitations of Use : Ixazomib is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials. Limitations of Use : Ixazomib is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials .

Reference Dosage and Administration

Recommended dosage as directed, because overdosage has led to deaths . taken orally on Days 1, 8, and 15 of a 28-day cycle.

Dose conversion must be confirmed by a physician because the reference dose may vary by indication, organ function, toxicity, or interacting medicines.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Thrombocytopenia : Monitor platelet counts at least monthly during treatment and adjust dosing, as needed. ( 2.2 , 5.1 ) Gastrointestinal Toxicities : Adjust dosing for severe diarrhea, constipation, nausea, and vomiting, as needed. ( 2.2 , 5.2 ) Peripheral Neuropathy : Monitor patients for symptoms of peripheral neuropathy and adjust dosing, as needed. ( 2.2 , 5.3 ) Peripheral Edema : Monitor for fluid retention. Investigate for underlying causes, when appropriate. ( 2.2 , 5.4 ) Cutaneous Reactions : Monitor patients for rash and adjust dosing, as needed. ( 2.2 , 5.5 ) Thrombotic Microangiopathy : Monitor for signs and symptoms. Discontinue Ixazomib if suspected. Hepatotoxicity : Monitor hepatic enzymes during treatment. Embryo-Fetal Toxicity : Ixazomib can cause fetal harm.

Common Adverse Reactions and Monitoring

The safety population from the randomized, double-blind, placebo-controlled clinical study included 720 patients with relapsed and/or refractory multiple myeloma, who received Ixazomib in combination with lenalidomide and dexamethasone (Ixazomib regimen; N=361) or placebo in combination with lenalidomide and dexamethasone (placebo regimen; N=359). One or more of the three drugs was permanently discontinued in 4% of patients reporting peripheral neuropathy, 3% of patients reporting diarrhea and 2% of patients reporting thrombocytopenia. Permanent discontinuation of Ixazomib due to an adverse reaction occurred in 10% of patients.

Drug Interactions and Special Populations

Strong CYP3A inducers : Avoid concomitant use with Ixazomib. ( 7.1 , 12.3 ) 7.1 Strong CYP3A Inducers Avoid concomitant administration of Ixazomib with strong CYP3A inducers (such as rifampin, phenytoin, carbamazepine, and St. Hepatic Impairment : Reduce the Ixazomib starting dose to 3 mg in patients with moderate or severe hepatic impairment. ( 2.3 , 8.6 ) Renal Impairment : Reduce the Ixazomib starting dose to 3 mg in patients with severe renal impairment or end-stage renal disease requiring dialysis. ( 2.4 , 8.7 ) Lactation : Advise not to breastfeed. There are no available data on Ixazomib use in pregnant women to evaluate drug-associated risk.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: NINLARO public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.